3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
43
Carcinoma, Hepatocellular
19
Rectal Neoplasms
10
Colonic Neoplasms
10
Neoplasm Metastasis
9
Gastrointestinal Stromal Tumors
8
Sarcoma
5
Ovarian Neoplasms
5
Cholangiocarcinoma
5
Melanoma
4
Pancreatic Neoplasms
3
Osteosarcoma
3
Liver Neoplasms
3
Glioblastoma
3
Stomach Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Gallbladder Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thyroid Neoplasms
1
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Interventions
Cisplatin
28
Pemetrexed
22
Gemcitabine
10
Nivolumab
9
Carboplatin
9
pembrolizumab
8
tremelimumab
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Doxorubicin
4
Chemotherapy, Adjuvant
4
Vinorelbine
3
Ipilimumab
3
Bortezomib
3
Bevacizumab
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
sodium thiosulfate
2
sargramostim
2
niraparib
2
nintedanib
2
liposomal doxorubicin
2
lenvatinib
2
defactinib
2
cemiplimab
2
cediranib
2
amatuximab
2
Trabectedin
2
Neoadjuvant Therapy
2
Mitomycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mesothelioma, Malignant
×
regorafenib
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn